1. Most Discussed
  2. Gainers & Losers
PBT 4.6¢

A sea of green except.....

  1. rising

    458 Posts.
    Yes a green watch list except for one stock.

    Its like they purposely chose Friday the 13th to announce this bad news, despite the day being very lucky for the majority of stocks.

    It highlights PBT inexperience with clinical trials and dealing with the FDA. I am sure if they were partnered with a big Pharma that all the i's would be dotted and the t's crossed. It seems quite incredulous that PBT would submit a higher dosage human trial for phase III without having any evidence either in animal models or early stage II human trials that such a dosage is not toxic.

    Whilst I am sure PBT is confident that a higher dose will be safe, it will set them back at least 6 to 12 months in obtaining the data unless they can provide the FDA with some existing safety data in the interim. The AD extension trial which I believe is due to report findings before end of March, continued to dose the patients using 250 mg. Lets hope that there is some good news from the extension trial as long-term share holders need some respite from the back to back bombshell announcements of the past year.

    Rudi Tanzi has developed a so called "Alzheimers in a dish", a cell culture model which is purports be able to perform drug trials in a petri dish taking a fraction of time to gain important information that would normally take years in clinical trials usually performed on animals. Don't think that the FDA would accept such data though.

    I guess you can say that it is a buying opportunity with the stock being at a 52 week low. Eventually PBT will supply the FDA with the data and hopefully they will get the nod for the phase III trial. It seems a bit odd though given the orphan status granted on PBT2 to potentially fast track the approval process that this decision will actually slow the process but in the end, the safety of patients is the FDA's main concern and priority.

Before making any financial decisions based on what you read, always consult an advisor or expert.

The HotCopper website is operated by Report Card Pty Ltd. Any information posted on the website has been prepared without taking into account your objectives, financial situation or needs and as such, you should before acting on the information or advice, consider the appropriateness of the information or advice in relation to your objectives, financial situation or needs. Please be aware that any information posted on this site should not be considered to be financial product advice.

From time to time comments aimed at manipulating other investors may appear on these forums. Posters may post overly optimistic or pessimistic comments on particular stocks, in an attempt to influence other investors. It is not possible for management to moderate all posts so some misleading and inaccurate posts may still appear on these forums. If you do have serious concerns with a post or posts you should report a Terms of Use Violation (TOU) on the link above. Unless specifically stated persons posting on this site are NOT investment advisors and do NOT hold the necessary licence, or have any formal training, to give investment advice.


Thank you for visiting HotCopper

We have detected that you are running ad blocking software.

HotCopper relies on revenue generated from advertisers. Kindly disable your ad blocking software to return to the HotCopper website.

I understand, I have disabled my ad blocker. Let me in!

Need help? Click here for support.